Table 1.

Basic characteristics of trials adopting routine on-site monitoring and hybrid monitoring.

Category		Routine on-site monitoring (n=91)	Hybrid monitoring (n=110)	P value
Trial phase , n (%)
	Phase I	18 (19.8)	27 (24.5)	.14
	Phase II	24 (26.4)	38 (34.5)
	Phase III	49 (53.8)	45 (40.9)
Blinding method , n (%)
	Yes	25 (27.5)	18 (16.4)	.06
	No	66 (72.5)	92 (83.6)
Medication category , n (%)
	Biologics	66 (72.5)	78 (70.9)	.80
	Chemicals	25 (27.5)	32 (29.1)
Administration , n (%)
	Single medication	43 (47.3)	53 (48.2)	.90
	Combination	48 (52.7)	57 (51.8)
Nature of the trial , n (%)
	Local	61 (67)	81 (73.6)	.51
	Multinational	30 (33)	29 (26.4)
Trial stage , n (%)
	Enrollment period	45 (49.5)	67 (60.9)	.10
	Follow-up period	46 (50.5)	43 (29.1)
Number of patients, mean (SD)		9.13 (12.739)	9.87 (11.669)	.44